The Effects of Colchicine on Inflammation Reduction in Patients with Acute Myocardial Infarction in Surin Hospital
Main Article Content
Abstract
BACKGROUND: In patients with acute myocardial infarction (AMI) receiving reperfusion therapy and the standard treatment for myocardial infarction, persistent elevated C-reactive protein (CRP) indicating high inflammation in the body can cause a high recurrence of cardiovascular diseases in the future. Colchicine is an anti-inflammatory drug, which has data confirming that it can reduce the incidence of cardiovascular diseases in patients with coronary artery disease (CAD).
OBJECTIVE: To study the effects of the inflammation reduction of 0.6 mg of colchicine in patients with AMI with primary percutaneous coronary intervention (PPCI) by focusing on hs-Trop I, CKMB, and CRP as the major results, whereas the left ventricular ejection fraction (LVEF) and side effects of the drugs would be the secondary results.
METHODS: The study consisted of 44 patients aged between 18-80 years diagnosed with AMI and successful PPCI in Surin Hospital, Surin, Thailand. They were randomized into two groups. The first group received a daily dosage of 0.6 mg of colchicine, and the second group received a placebo. Both received the drugs for 14 days. All patients were treated in accordance with the standard treatment for myocardial infarction. The differences of hs-Trop I, CKMB, CRP, and the left ventricular ejection fraction were observed, along with the side effects of colchicine and the placebo at the end of the study.
RESULTS: When comparing 0.6mg of colchicine with the placebo given to the patients, no difference was found from the primary data in both groups, i.e., age, sex, and risk factors; such as, diabetes, hypertension, smoking, and side effects from the drugs. Furthermore, no difference of hs-Trop I was found from the start of the study, day 1, 2, 3, 4, and day 14 (p=0.15, 0.11, 0.96, 0.71, 0.46, and 0.23, respectively), CKMB (p=0.65, 0.91, 0.41, 0.58, and 0.66, respectively), and CRP (p=0.86, 0.97, 0.75, 0.53, 0.67, and 0.52, respectively). There was also no difference of the left ventricular ejection fraction found on Day 1 and Day 14 as well (p=0.78 and 0.67).
CONCLUSIONS: According to the study, the inflammatory response of colchicine in patients with AMI did not show any inflammation reduction when compared with the placebo.
Thaiclinicaltrials.org number, TCTR20210127002
Article Details
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Moreira DM, da Silva RL, Vieira JL, Fattah T, Lueneberg ME, Gottschall CA. Role of vascular inflammation in coronary artery disease: potential of anti- inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Am J Cardiovasc Drugs 2015;15:1-11.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. antiinflammatory therapy with canakinumab for atherosclerotic Disease. N Engl J Med 2017; 377:1119-31.
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-Dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019 ;380:752-62.
Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol 2013;62:1817-25.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020; 383:1838-47.
Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep [Internet].2020 [cited 2021 Nov11];22(11):66. Avalilable from: https://doi.org/10.1007/s11883-020-00883-3
Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, et al. Anti-Inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation 2015;132:1395-403.
Akodad M, Lattuca B, Nagot N, Georgescu V, Buisson M, Cristol JP, et al. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch Cardiovasc Dis 2017;110:395-402.
Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, et al. The Low dose colchicine after myocardial infarction (LoDoCo MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 2019;215:62-9.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019 26;381:2497-505.
Mehta A, Mahtta D, Gulati M, Sperling LS, Blumenthal RS, Virani SS. Cardiovascular disease prevention in focus: highlights from the 2019 American Heart Association Scientific Sessions. Curr Atheroscler Rep [Internet]. 2020[cited 2021 Nov 11];22(1):3. Available from: https://doi.org/10.1007/s11883-020-0822-6
Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiova scular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes 2021;7:486-95.